

New Products

高齢者と高リスク者への肺炎球菌ワクチン

新規の3剤は効力も安全も評価なし、死亡が増える

薬のチェック編集委員会

参考文献

- 1) 国立健康危機管理研究機構、国立感染症研究所、成人用肺炎球菌ワクチンファクトシート2025/7/4 https://id-info.jihs.go.jp/relevant/vaccine/topics/140/Pneumococcal_20250704.pdf
- 2) ニューモバックス NP、審査報告書 2006 年、添付文書
- 3) ニューモバックス NP 再審査報告書 2016 年
- 4) プレベナー20、審査報告書、添付文書
- 5) バクニューバンス、審査報告書、添付文書
- 6) キャップボックス、審査報告書、添付文書
- 7) 日本小児科学会 予防接種・感染症対策委員会、小児における肺炎球菌結合型ワクチンの定期接種に関する考え方 2024 年 10 月 29 日 https://www.jpeds.or.jp/modules/activity/index.php?content_id=622
- 8) 薬のチェック編集委員会、肺炎球菌結合型ワクチン、薬のチェック 2017 ; 17 (70) : 28-31.
- 9) Bonten MJ, Huijts SM, Bolkenbaas Met al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. *N Engl J Med.* 2015 Mar 19;372(12):1114-25. doi: 10.1056/NEJMoa1408544. PMID: 25785969
- 10) 浜六郎、本沢龍生、Hib ワクチン・肺炎球菌ワクチンと死亡について、TIP 2011 ; 26(4) : 54-61
- 11) 浜六郎、ヒブ・肺炎球菌ワクチンの接種再開は時期尚早、薬のチェックは命のチェック 2011; 11(43):58-68.
- 12) 浜六郎、小児への肺炎球菌ワクチン、Hib (ヒブ) ワクチンは? 薬のチェック 2017; 17(72): 83-86.
- 13) 薬のチェック編集委員会、ヒブワクチンと肺炎球菌ワクチン、薬のチェック 2023; 23(106): 30-31.
- 14) 日本呼吸器学会成人肺炎診療ガイドライン 2024 作成委員会、成人肺炎診療ガイドライン 2024 https://www.jrs.or.jp/publication/file/adult_pneumonia_2024v5.pdf
- 15) 人口動態統計、<https://www.e-stat.go.jp/stat-search/files?page=1&toukei=00450011&tstat=000001028897>
- 16) Simberkoff M, Cross A, Al-Ibrahim M et al. Efficacy of pneumococcal vaccine in high-risk patients. *N Engl J Med.* 1986 Nov 20;315(21):1318-27. doi: 10.1056/NEJM198611203152104. PMID: 3534568
- 17) Maruyama T, Taguchi O, Niederman MS et al Efficacy of 23-valent pneumococcal vaccine in preventing pneumonia and improving survival in nursing home residents: double blind, randomised and placebo controlled trial. *BMJ.* 2010 Mar 8;340:c1004. doi: 10.1136/bmj.c1004. PMID: 20211953
- 18) French N, Gordon SB, Mwalukomo T et al. A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. *N Engl J Med.* 2010 Mar 4;362(9):812-22. doi: 10.1056/NEJMoa0903029. PMID: 20200385
- 19) Alfageme I, Vazquez R, Reyes N et al. Clinical efficacy of anti-pneumococcal vaccination in patients with COPD. *Thorax.* 2006 Mar;61(3):189-95. doi: 10.1136/thx.2005.043323. Epub 2005 Oct 14. PMID: 16227328
- 20) Kawakami K, Ohkusa Y, Kuroki R, et al. Effectiveness of pneumococcal polysaccharide vaccine against pneumonia and cost analysis for the elderly who receive seasonal influenza vaccine in Japan. *Vaccine* 2010; 28(43): 7063-9.
- 21) Furumoto A, Ohkusa Y, Chen M et al Additive effect of pneumococcal vaccine and influenza vaccine on acute exacerbation in patients with chronic lung disease. *Vaccine.* 2008 Aug 5;26(33):4284-9. doi: 10.1016/j.vaccine.2008.05.037. Epub 2008 Jun 5. PMID: 18585831
- 22) French N, Nakiyingi J, Carpenter LM et al. 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial. *Lancet.* 2000 Jun 17;355(9221):2106-11. doi: 10.1016/s0140-6736(00)02377-1. PMID: 10902624
- 23) Moberley S, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. *Cochrane Database Syst Rev* 2013; 2013(1): Cd000422.
- 24) Streeter AJ, Rodgers LR, Masoli J, Lin NX, Blé A, Hamilton W, et al. Real-world effectiveness of pneumococcal vaccination in older adults: Cohort study using the UK Clinical Practice Research Datalink. *PLoS ONE.* 2022;17(10):e0275642.

- 25) Nakashima K, Suzuki K, Aoshima M et al (Pneumonia in Elderly People Study Group) Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against community-acquired pneumonia in older individuals after the introduction of childhood 13-valent pneumococcal conjugate vaccine: A multicenter hospital-based case-control study in Japan. *Vaccine*. 2022 Nov 2;40(46):6589-6598. doi: 10.1016/j.vaccine.2022.09.055. Epub 2022 Sep 30. PMID: 36184405
- 26) Heo JY, Seo YB, Choi WS, et al. Effectiveness of Pneumococcal Vaccination Against Pneumococcal Pneumonia Hospitalization in Older Adults: A Prospective, Test-Negative Study. *J Infect Dis*2022; 225(5): 836-45.
- 27) Andrews NJ, Waight PA, George RC, Slack MPE, Miller E. Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales. *Vaccine*2012; 30(48): 6802-8.
- 28) Lawrence H, Pick H, Baskaran V, et al. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against vaccine serotype pneumococcal pneumonia in adults: A case-control test-negative design study. *PLoS Med*2020; 17(10): e1003326.
- 29) Prescrire team. Pneumococcal conjugate vaccine: do not routinely vaccinate adults aged 65 years and older. *Prescrire International*. 2016 : 25(172) : 157-58.
- 30) 渡邊裕美、浜六郎、ワクチン観察研究における健康者接種バイアスの理論と実例（未発表論文）